AstraZeneca
NEWS
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.
AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AstraZeneca has a problem. Not with its pipeline, but with the way a significant chunk of shareholders views its executive pay program.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.
JOBS
IN THE PRESS